Jeremy Springhorn Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jeremy Springhorn sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the sale, the director directly owned 43,251 shares in the company, valued at approximately $1,170,372.06. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

uniQure Stock Up 2.8%

Shares of QURE stock opened at $27.57 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm’s 50-day moving average is $22.52 and its 200-day moving average is $21.80. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Sell-side analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Torren Management LLC bought a new position in uniQure in the 4th quarter valued at about $28,000. Jones Financial Companies Lllp raised its holdings in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the period. IFP Advisors Inc bought a new position in uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC bought a new position in uniQure in the 4th quarter valued at about $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth approximately $50,000. 78.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on QURE. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $15.00 to $60.00 in a report on Monday, March 9th. HC Wainwright lowered their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $11.00 to $35.00 in a report on Monday, March 9th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.83.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.